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Nasopharyngeal carcinoma (NPC) is highly preva­
lent in southern China, with incidence rates of 15–50 
per 100,000 [1]. Although as a subtype of head and 
neck carcinoma, NPC is unique in epidemiology, clinical 
cha racteristics, etiology and histopathology. Compared 
with other head and neck squamous cell carcinomas, 
NPC tends to present at a more advanced stage of 
disease and exhibits higher metastatic potential [2, 
3]. Despite advances in diagnosis and treatment, the 
survival rate for patients with NPC remains unchanged 
in the past years. To guide treatment and improve prog­
nosis, identification of new biomarkers is required.
Destruction of surrounding tissues, such as the extra­
cellular matrix and basement membrane, is an essential 
component of tumor invasion and metastasis. Many pro­
teolytic enzymes are known to be involved in this process, 
including cysteine, aspartyl and serine proteases [4]. 
Cathepsins belong to lysosomal hydrolases that degrade 
proteins in lysosomes at an acidic pH, and are composed 
of several classes, such as cathepsin A, B, C, D, H, L. 
Of the cathepsin subtypes, cathepsin L, also known as 
MEP (major excreted protein), was reported to be more 
potent than the other cathepsin classes in degrading 
extracellular matrix components [5]. Chauhan et al. [6] 
demonstrated that cancers in general express higher le­
vels of cathepsin L than normal tissues, including kidney, 
testicular, lung, breast, ovary, colon, adrenal, bladder, 
prostate, thyroid tumors. Cathepsin L has previously been 
found to correlate with metastatic potential in a number 
of model tumor systems, both in vivo and in vitro [7], and 
has been associated with outcome in a number of human 
cancers [8]. However, information on the relationship 
between cathepsin L and NPC is limited.
In this study, we examined the expression of cathe­
psin L in primary NPC, adjacent normal nasopharyn­
geal tissues and metastatic cervical lymph nodes by 
immunohistochemistry, and analyzed the relationship 
between its expression and clinicopathologic factors 
and follow­up data of NPC patients.
MATERIALS AND METHODS
Patients. Eighty­five patients with nasopharyngeal 
carcinoma (NPC) were included in this study. Their 
diagnosis was confirmed from 1999 to 2002 via na­
sopharyngeal biopsies at the Department of Pathology 
of Renmin Hospital of Wuhan University. All the patients 
presented no distant metastasis at their diagnosis. The 
patients received irradiation only or combined irradia­
tion and chemotherapy. Clinical data on patient age, 
gender, stage of disease, histopathological classifica­
tion (WHO) were collected. The median follow­up time 
was 61 months (range, 11 to 70 months). The 1992 NPC 
staging system of China was used for tumor staging [9], 
and the histopathological grade was defined according 
to WHO criteria. Our study was approved ethically by the 
institutional review board of Wuhan University.
Immunohistochemical staining. The expressions 
of cathepsin L in NPC, adjacent normal nasopharyn­
geal tissues and metastatic cervical lymph nodes, 
were detected by immunohistochemistry. The tissue 
sections were deparaffinized in xylene twice for 10 min 
each, progressively hydrated in graded ethanol, and 
then immersed in 3% hydrogen peroxide to quench 
endogenous peroxidase. Nonspecific binding sites 
were blocked by incubating the sections in 10% normal 
rabbit serum for 10–15 min. The sections were then 
incubated with mouse anti­human cathepsin L mono­
clonal antibody (dilution 1 : 1000; Jing Mei Biotechno­
logy Co.) at 4 °C overnight, followed by incubation with 
biotinylated goat­anti­mouse secondary antibody 
(Boster Biotechnology Co.) conjugated to horseradish 
peroxidase (HRP) at room temperature for 10–15 min. 
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The staining was developed with 3,3’­diaminobenzi­
dine tetrahydrochloride and hydrogen peroxide, and 
the sections were counterstained with hematoxylin and 
mounted. For positive controls, a section of human 
liver tissue was used in each assay. Negative controls 
for all immunostainings were derived by substituting 
the primary antibody with normal rabbit serum.
Evaluation of immunostaining. The immunos­
tained sections were observed under high­power 
magnification (× 200) and were evaluated indepen­
dently by two pathologists without knowledge of 
the clinicopathologic details. Scoring of the immu­
nohistochemical results was performed according 
to the methods described by Sinicrope et al. with 
minor modifications [10]. Briefly, the positive tumor 
cells were quantified, expressed as the percentage 
of the total number of tumor cells, and assigned to 
one of 5 categories: 0, ≤ 5%; 1, 5–25%; 2, 25–50%; 
3, 50–75%; and 4, ≥ 75%. The immunointensity was 
graded as: 1+, weak; 2+, moderate; and 3+, intense. 
Immunoreactivity scores for each case were produced 
by multiplication of the values for the two parameters. 
Cases with scores ≥ 3 were considered as over­
expression of cathepsin L.
Statistical analysis. Data were analyzed using 
SPSS 12.0 software. The chi­square test was used to 
analyze the relation between cathepsin L expression 
and clinicopathologic characteristics. Survival curves 
were plotted by the Kaplan — Meier method and com­
pared by the log­rank test in relation to cathepsin L 
expression. Multivariate analysis was performed by 
Cox’s proportional hazards regression model. P ≤ 0.05 
was considered statistically significant.
RESULTS
Patient or tumor characteristics. Patients con­
sisted of 61 men and 24 women, and their age ranged 
in age from 24 to 66 years at the moment of diagnosis 
(mean, 47 years). Patient and tumor characteristics are 
presented in Table 1.
Table 1. Correlation between clinical pathological features and 
cathepsin L expression in nasopharyngeal carcinoma
Characteristics Number of patients
Number (%) of cathepsin 
L overexpression P value
Normal tissues 20 0
NPC 85 40 (47%)
Metastatic lymph nodes 18 16 (89%)
Age (years)
≤ 45 40 18 (45.0%) 0.72
> 45 45 22 (48.9%)
Gender
Male 61 30 (49.2%) 0.532
Female 24 10 (41.7%)
Stage
I + II 27 9 (33.3%) 0.084
III + IV 58 31 (53.4%)
T classification
T1 + T2 36 13 (36.1%) 0.083
T3 + T4 49 27 (55.1%)
Lymph node metastasis
Negative 19 5 (26.3%) 0.04
Positive 66 35 (53.0%)
Distant metastasis
Negative 65 18 (27.7%) 0.01
Positive 20 12 (60.0%)
Histological classification
Type II 21 10 (47.6%) 0.953
Type III 64 30 (46.9%)
Expression of cathepsin L. The expression of 
cathepsin L protein was observed in the cytolplasm of 
tumor cells and extracellular matrix adjacent to lesional 
cells. The immunostaining was shown as fine to coarse 
granular staining. The protein was overexpressed in 
47% of primary tumor tissues, and in 89% metastatic 
cervical lymph node samples (Fig. 1, a, b). However, 
there was little immunoreactivity in the adjacent normal 
tissues (Fig. 1, c).
a
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c
Fig. 1. Immunohistochemical analysis of cathepsin L expression. 
a, b, Overexpression of cathepsin L in NPC and metastatic lymph 
nodes; c, Negative expression in adjacent normal tissue. Original 
magnification x 100 or 200
Relation between cathepsin L expression and 
clinicopathologic factors, and follow-up data. 
The relationship between the expression of cathepsin 
L protein and various clinicopathologic features was 
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summarized in Table 1. There was no significant cor­
relation between the expression of cathepsin L protein 
and age, gender of NPC patients, and histological 
classification of tumor. However, overexpression of 
cathepsin L was significantly associated with lymph 
node metastasis (P = 0.04), distant metastasis (P = 
0.01), and marginally with clinical stage and T clas­
sification, as compared with tumors without cathepsin 
L overexpression.
The 5­year survival rate, assessed by the Kaplan — 
Meier method, was 75.6% in patients without overex­
pression of cathepsin L in tumor tissue; whereas it was 
only 52.5% in those with its overexpression. There was 
a negative correlation between 5­year survival rate and 
cathepsin L protein overexpression. That is, there was 
a significantly lower 5­year survival rate in patients 
with cathepsin L protein overexpression than in those 
without it (Fig. 2; log­rank test: P = 0.033).
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Fig. 2. Survival curves of patients with NPC, subdivided 
 according to cathepsin L level
Besides cathepsin L protein expression level, T and 
N classification, and clinical stage were also signifi­
cantly correlated with survival in Kaplan — Meier analy­
sis and Log­rank test (for T classification, P = 0.02; for 
N classification, P = 0.012; for clinical stage, P < 0.001). 
We performed multivariate survival analysis, which 
included cathepsin L protein expression level, T and 
N classification, and clinical stage of the disease to 
determine whether cathepsin L protein expression 
level is an independent prognostic factor of outcome. 
The results showed that clinical stage was recognized 
as an independent prognostic factor, and cathepsin 
L protein expression level had a marginal significant 
correlation with prognosis of NPC (Table 2).
Table 2. Multivariate analysis of different prognostic variables 
in 85 patients with NPC by Cox’s regression model
Factors β value Standard error value P value
T classification 0.512 0.467 0.273
N classification 1.06 0.748 0.153
Clinical stage 2.393 1.038 0.021
Cathepsin L expression –0.686 0.385 0.055
DISCUSSION
Proteases have been thought to play a role in tu­
mor invasion and metastasis due to their destructive 
effects on extracellular matrix. As a lysosomal thiol 
protease, cathepsin L is more potent than many other 
cathepsin classes in degrading extracellular matrix as 
well as basement membrane components [5, 6]. It is 
synthesized and secreted in latent form. Cathepsin D 
and specific metalloproteases may play a role in its 
activation [11, 12]. Cathepsin L can also undergo 
autoactivation [13]. We assessed the protein level of 
cathepsin L semiquantitatively in NPC using immu­
nohistochemical method with a specific monoclonal 
antibody that can discriminate between cathepsin L 
and other cathepsin classes but react with both active 
and latent forms. Therefore, the present data revealed 
not enzyme activity but the potential of the tumor to 
produce cathepsin L. In the present study, we showed 
that cathepsin L was more highly expressed in the 
primary NPC tissues than in normal nasopharyngeal 
tissues. Furthermore, the protein was overexpressed in 
the metastatic cervical lymph node samples. Cancers 
in general have been demonstrated to exrpess higher 
levels of cathepsin L than normal tissues, including 
kidney, testicular, lung, breast, ovary, colon, adrenal, 
bladder, prostate, thyroid tumors [6].
A large body of literature has accumulated to sug­
gest that cathepsin L is involved in tumor invasion and 
metastasis. Alterations in the expression at protein or 
mRNA levels, as well as in the activity of the protease, 
have been found to correlate with malignancy of vari­
ous murine and human tumors [14]. Overexpression 
of cathepsin L has been shown to be related to survival 
in clinical studies of malignant melanoma, breast, co­
lorectal, gastric and brain cancers [15–19]. In the cur­
rent study, we found that overexpression of cathepsin 
L in NPC was associated with lymph node metastasis 
and distant metastasis, and marginally with clinical 
stage and T classification. Expression of cathepsin 
L was also closely related to long­term outcome of 
patients with NPC. Patients with overexpression of 
cathepsin L in NPC tissue had a poorer 5­year survival 
rate than those without it. Multivariate survival analysis 
showed that cathepsin L protein expression level had 
a marginal significant correlation with prognosis of 
NPC. So, cathep sin L contributes to NPC metastasis 
and may be used as a potential biomarker for prog­
nosis of NPC.
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